Viewing Study NCT04837651

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:47 PM
Ignite Modification Date: 2026-03-09 @ 4:05 AM
Study NCT ID: NCT04837651
Status: COMPLETED
Last Update Posted: 2021-08-02
First Post: 2021-03-16
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Sponsor: Dragonfly Research, LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Sclerosis View
None Demyelinating Autoimmune Diseases, CNS View
None Autoimmune Diseases of the Nervous System View
None Nervous System Diseases View
None Demyelinating Diseases View
None Autoimmune Diseases View
None Immune System Diseases View
None Pathologic Processes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None COVID-19 View
None Natalizumab View
None Ocrelizumab View
None Ocrevus View
None Tysabri View
None Antibody View
None Coronavirus View
None Vaccine View